Hormone Replacement Therapy and Sensitive C-reactive Protein Concentrations in Women with Type-2 Diabetes

Overview

Journal Lancet

Publisher Elsevier

Specialty General Medicine

Date 1999 Aug 28

PMID 10465182

Citations 7

Authors

N Sattar

M Perera

M Small

M A Lumsden

Affiliations

Soon will be listed here.

Abstract

C-reactive protein concentrations as a marker of inflammation predicts vascular risk and is raised in type-2 diabetes. In a 6-month double-blind placebo controlled trial, a combination of transdermal oestradiol 80 microg with continuous oral norethisterone 1 mg significantly reduced C-reactive protein concentrations in postmenopausal women with type-2 diabetes.

Citing Articles

Role of C-Reactive Protein at Sites of Inflammation and Infection.

Sproston N, Ashworth J Front Immunol. 2018; 9:754.

PMID: 29706967 PMC: 5908901. DOI: 10.3389/fimmu.2018.00754.

What is the influence of hormone therapy on homocysteine and crp levels in postmenopausal women?.

Lakryc E, Bonassi Machado R, Soares Jr J, Fernandes 3rd C, Baracat E Clinics (Sao Paulo). 2015; 70(2):107-13.

PMID: 25789519 PMC: 4424426. DOI: 10.6061/clinics/2015(02)07.

Dual-port distal gastrectomy for the early gastric cancer.

Kashiwagi H, Kumagai K, Monma E, Nozue M Surg Endosc. 2014; 29(6):1321-6.

PMID: 25159658 PMC: 4422851. DOI: 10.1007/s00464-014-3827-9.

The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial.

Lazzeroni M, Macis D, DeCensi A, Gandini S, Sandri M, Serrano D Ecancermedicalscience. 2012; 2:67.

PMID: 22275964 PMC: 3234057. DOI: 10.3332/ecancer.2008.67.

Transdermal hormone therapy in postmenopausal women: a review of metabolic effects and drug delivery technologies.

Kopper N, Gudeman J, Thompson D Drug Des Devel Ther. 2009; 2:193-202.

PMID: 19920906 PMC: 2761184. DOI: 10.2147/dddt.s4146.